Friday, June 12, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 141 of 1,261
  1. US 11884736

    Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  2. US 11884945

    Methods for purification of arylsulfatase A

    Takeda Pharmaceutical Company Limited Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  3. US 11883383

    Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine

    VTV THERAPEUTICS LLC Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  4. US 11884647

    Compounds and methods for targeting pathogenic blood vessels

    The Regents of the University of California Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  5. US 11883223

    Hepatic inflammation analysis with dynamic PET

    The Regents of the University of California Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  6. US 11883386

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  7. US 11885807

    Method for depleting malignant T-cells

    AUTOLUS LIMITED Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  8. US 11883381

    ASH1L inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  9. US 11882920

    Systems, devices and methods for styling hair

    MIRAKEL TECHNOLOGIES, INC. Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  10. US 11884748

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  11. US 11884740

    Anti-CD20 antibody compositions

    TG Therapeutics, Inc. Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  12. US 11884672

    Modulators of alpha-1 antitrypsin

    Vertex Pharmaceuticals Incorporated Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  13. US 11884718

    Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination

    The Government of the United States, as represented by the Secretary of the Army Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  14. US 11884710

    Peptide compounds and methods of use in wound healing

    The Board of Regents of the University of Oklahoma Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  15. US 11883475

    Infectious Plasmodium sporozoites grown in vitro

    Sanaria Inc. Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  16. US 11883492

    Combination treatment of chemoresistant cancers

    The Regents of the University of California Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  17. US 11883359

    Adapter for use in a planetary mixer

    MEDISCA PHARMACEUTIQUE INC. Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  18. US 11883433

    Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof

    CELLENGENE INC. Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  19. US 11884930

    Method of inactivating a glucocorticoid receptor gene in an isolated cell

    Sangamo Biosciences, Inc. Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  20. US 11883431

    T-cells modified to overexpress PHF19

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  21. US 11885806

    Method for depleting malignant T-cells

    AUTOLUS LIMITED Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  22. US 11883408

    Reboxetine to treat narcolepsy

    AXSOME THERAPEUTICS, INC. Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  23. US 11883423

    Nucleobase analogue derivatives and their applications

    The Board of Regents of the University of Texas System Β· Granted Jan 30, 2024 Β· Expires Jan 25, 2044

    granted
  24. CA 3262048

    CX3CR1-BINDING COMPOUNDS, METHODS AND USES THEREOF

    SANOFI SA [FR] Β· Granted Jan 25, 2024 Β· Expires Jan 20, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.